Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 08, 2026 06:00 ET | Source: JD.com, Inc.

JD.com Announces Updates of Share Repurchase and Cancellation

BEIJING, Jan. 08, 2026 (GLOBE NEWSWIRE) -- JD.com, Inc. (NASDAQ: JD and HKEX: 9618 (HKD counter) and 89618 (RMB counter), the “Company” or “JD.com”), a leading supply chain-based technology and...
January 06, 2026 20:00 ET | Source: ASCENTAGE PHARMA GROUP INTERNATIONAL

Ascentage Pharma Announces IND Clearance by the U.S. Food and Drug Administration for BTK Degrader APG-3288

Novel next-generation Bruton tyrosine kinase (BTK)-targeted protein degrader APG-3288 has received investigational new drug (IND) clearance from the U.S. FDA, marking another major expansion to the...
January 06, 2026 19:00 ET | Source: HUTCHMED (China) Limited

HUTCHMED Announces Positive Topline Results of Phase III Part of ESLIM-02 Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China

— Delivers rapid, durable responses in wAIHA, the more common form of this potentially life-threatening disease — HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Jan. 07, 2026 (GLOBE NEWSWIRE) --...
January 05, 2026 07:00 ET | Source: Seyond Inc

Seyond to Showcase Live RoboVan Demonstrations and Next-Generation LiDAR at CES 2026

LAS VEGAS, Jan. 05, 2026 (GLOBE NEWSWIRE) -- As CES 2026 opens this week, Seyond, a global leader in high-performance LiDAR solutions, invites attendees to experience live autonomous demonstrations...
January 04, 2026 19:00 ET | Source: HUTCHMED (China) Limited

HUTCHMED Initiates Phase III Stage of the Ongoing Trial of the Combination of Surufatinib and Camrelizumab for Treatment-Naïve Pancreatic Ductal Adenocarcinoma

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Jan. 05, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated the Phase III...
January 01, 2026 03:00 ET | Source: NIO Inc.

NIO Inc. Provides December, Fourth Quarter and Full Year 2025 Delivery Update

48,135 vehicles were delivered in December 2025, increasing by 54.6% year-over-year124,807 vehicles were delivered in the three months ended December 2025, increasing by 71.7% year-over-year326,028...
December 31, 2025 21:00 ET | Source: Li Auto Inc.

Li Auto Inc. December 2025 Delivery Update

BEIJING, China, Jan. 01, 2026 (GLOBE NEWSWIRE) -- Li Auto Inc. (“Li Auto” or the “Company”) (Nasdaq: LI; HKEX: 2015), a leader in China’s new energy vehicle market, today announced that it delivered...
December 30, 2025 08:00 ET | Source: Seyond Inc

Seyond Announces $2.6M Collaboration with Aventi Sweden to Enhance Market Presence

Seyond today announced a new agreement to deploy its advanced detection technology across key traffic infrastructure locations in Sweden.
December 30, 2025 05:00 ET | Source: HUTCHMED (China) Limited

HUTCHMED Announces NDA Acceptance in China with Priority Review Status for Savolitinib for the treatment of Gastric Cancer Patients with MET Amplification

— NDA supported by positive Phase II registration study data in Chinese patients; follows Breakthrough Therapy Designation granted in 2023 — — Savolitinib has the potential to become the first...
December 29, 2025 03:35 ET | Source: HUTCHMED (China) Limited

HUTCHMED Announces NDA Acceptance in China with Priority Review Status for Fanregratinib in Second-Line Intrahepatic Cholangiocarcinoma

— NDA supported by results from a Phase II registration trial in China — — Second most common form of liver cancer after hepatocellular carcinoma, with generally poorer long-term survival in...